NCT06561542View on ClinicalTrials.gov

A Phase I Study of LX22001 for Injection in Healthy Subjects

PHASE1RecruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

August 5, 2024

Primary Completion Date

November 21, 2025

Study Completion Date

November 21, 2025

Conditions
Healthy
Interventions
DRUG

LX22001 for Injeciton

single dose: 25mg,50mg,100mg,200mg ,intravenous infusion. repeat doses: 50mg,100mg , intravenous infusion,once daily for 3 days.

DRUG

Tegoprazan tablet

50mg,oral,single dose

DRUG

Esomeprazole sodium for injection

80 mg intravenous infusion for 30 min followed by a continuous infusion of 8 mg/h for 71.5h

Trial Locations (1)

100730

RECRUITING

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors
lead

Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.

INDUSTRY